{"filings":[{"id":918318,"accession_number":"0001493152-26-027717","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-06-08T20:10:41+00:00","items":["1.01","1.02","2.03","8.01","9.01"],"status":"ready","headline":"Celcuity closes $575M convertible note offering at 0.250% due 2032, repays $137.5M loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $575M aggregate principal of 0.250% Convertible Senior Notes due 2032; net proceeds ~$557M.","Initial conversion rate 8.0302 shares/$1,000 principal (~$124.53/share, ~40% premium to June 3 close).","Used ~$137.5M of net proceeds to fully repay and terminate existing loan agreement with Oxford Finance and Innovatus.","Remaining proceeds for working capital, clinical/commercial launch costs, and general corporate purposes.","Notes redeemable at Celcuity's option after Aug 6, 2029 if stock exceeds 130% of conversion price for 20 of 30 trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787997,"accession_number":"0001493152-26-026761","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-06-02T12:10:25+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gedatolisib-triplet reduced risk of progression or death by 50% (HR=0.50; p<0.0001); median PFS 11.1 vs 5.6 months.","ORR 48.9% for triplet vs 26.0%; median DOR 15.7 vs 7.5 months for alpelisib+fulvestrant.","Grade 3+ TRAEs: neutropenia 58.8% (triplet) vs 0.7%; discontinuation rate 2.6% vs 7.1%.","Company plans sNDA submission following positive PIK3CA MT cohort; PDUFA for NDA in WT cohort July 17, 2026.","Commercial launch expected in Q3 2026 pending FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":536277,"accession_number":"0001493152-26-024510","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K/A","filed_at":"2026-05-20T11:30:22+00:00","items":["5.02"],"status":"ready","headline":"Celcuity appoints Charles R. Romp to board; board expands from 7 to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 members; Charles R. Romp appointed as director effective Feb 11, 2026.","Mr. Romp qualifies as an independent director under Nasdaq and SEC rules.","On May 14, 2026, appointed to Compensation Committee and Nominating & Corporate Governance Committee.","Compensation: $70k annual cash retainer, $135k annual equity award, initial 215 restricted shares vesting Apr 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499043,"accession_number":"0001493152-26-024175","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-05-18T20:05:38+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celcuity stockholders approve 2026 equity plan (3M shares) and amended ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2026 Stock Incentive Plan authorizing 3,000,000 shares of common stock for equity awards.","Stockholders approved the Amended and Restated ESPP, increasing share reserve by 289,199 shares and extending expiration ten years.","All eight director nominees elected; Richard Nigon and Charles Romp each received over 37.6M 'for' votes.","Ratified Boulay PLLP as independent auditor for FY2026 with 40.9M 'for' votes; advisory 'say-on-pay' approved with 35.8M 'for'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442519,"accession_number":"0001493152-26-023065","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-05-14T20:05:21+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity reports Q1 net loss $52.8M; VIKTORIA-1 hits primary endpoint in PIK3CA mutant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $52.8M ($0.97/share) vs $37.0M ($0.86/share) in Q1 2025; non-GAAP adjusted net loss $46.8M ($0.86).","VIKTORIA-1 PIK3CA mutant cohort: gedatolisib triplet and doublet both achieved statistically significant PFS improvement vs alpelisib+fulvestrant.","Detailed VIKTORIA-1 data to be presented at ASCO LBA oral session on June 2, 2026; sNDA submission planned for Q3 2026.","NDA for gedatolisib in PIK3CA wild-type accepted with Priority Review; PDUFA date July 17, 2026.","VIKTORIA-2 expanded: Study 2 (~740 patients) evaluating gedatolisib as first-line in endocrine-sensitive HR+/HER2- advanced breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94013,"accession_number":"0001493152-26-020918","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Celcuity Phase 3 VIKTORIA-1 PIK3CA mutant cohort meets primary endpoint with significant PFS improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gedatolisib triplet (plus fulvestrant and palbociclib) showed statistically significant PFS improvement vs alpelisib+fulvestrant.","Gedatolisib doublet (plus fulvestrant) also achieved statistically significant PFS improvement as secondary endpoint.","Both regimens were generally well tolerated with manageable safety profiles and no new safety signals.","Celcuity plans sNDA submission to FDA; detailed results will be presented at ASCO 2026 on June 2.","FDA previously granted Priority Review for NDA in PIK3CA wild-type cohort with PDUFA date July 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106066,"accession_number":"0001493152-26-012668","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity reports Q4 loss $0.97/share; FDA grants Priority Review for gedatolisib, PDUFA July 17, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $51.0M ($0.97), FY $177.0M ($3.79); adjusted net loss Q4 $38.4M ($0.73), FY $150.8M ($3.22).","FDA accepted NDA for gedatolisib in HR+/HER2-/PIK3CA WT advanced breast cancer, granted Priority Review; PDUFA goal date July 17, 2026.","Topline results from PIK3CA mutant cohort of Phase 3 VIKTORIA-1 expected in Q2 2026.","Updated efficacy/safety results from PIK3CA WT cohort published in Journal of Clinical Oncology in March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106065,"accession_number":"0001493152-26-006444","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Celcuity appoints Charles Romp to board of directors; brings commercial oncology expertise","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles (Chip) R. Romp appointed to board, effective Feb 11, 2026; board size increased from 7 to 8.","Romp is CEO of Secura Bio, previously EVP Commercial at Seagen (sold to Pfizer), with 25+ years oncology experience.","He will receive $50k annual cash retainer, $100k annual equity award, and pro-rated grant of 215 restricted shares vesting by 2026 annual meeting or April 30.","Company notes preparation for potential approval and launch of gedatolisib later this year (HR+/HER2- advanced breast cancer).","Romp qualifies as independent under Nasdaq and SEC rules; no committee assignments yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122364,"accession_number":"0001493152-25-023897","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Celcuity completes NDA submission to FDA for gedatolisib in HR+/HER2- advanced breast cancer under RTOR program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer.","Submitted under FDA's RTOR program; drug previously received Breakthrough Therapy and Fast Track designations.","Phase 3 VIKTORIA-1: triplet reduced risk of progression/death by 76% (HR 0.24); median PFS 9.3 mo vs 2.0 mo.","Doublet (gedatolisib + fulvestrant) reduced risk by 67% (HR 0.33); median PFS 7.4 mo vs 2.0 mo.","CEO Sullivan: 'unprecedented efficacy results and overall safety profile are potentially practice changing.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122363,"accession_number":"0001493152-25-021903","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q3 net loss $43.8M; gedatolisib NDA on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $43.8M ($0.92 loss per share) vs $29.8M ($0.70 loss) in prior year.","Operating expenses $42.8M (R&D $34.9M, G&A $7.9M), up from $30.1M.","PIK3CA WT cohort: gedatolisib triplet reduced risk of progression/death by 76% (HR 0.24); median PFS 9.3 vs 2.0 months.","FDA accepted NDA under RTOR program; submission for gedatolisib on track for Q4 2025.","PIK3CA mutant cohort fully enrolled; topline data expected late Q1 2026 or Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122362,"accession_number":"0001493152-25-018565","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Phase 3 VIKTORIA-1 data: gedatolisib triplet reduces progression risk by 76% in HR+/HER2- ABC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS 9.3mo for gedatolisib triplet vs 2.0mo for fulvestrant (HR=0.24); incremental 7.3mo improvement.","ORR 31.5% for triplet vs 1% for fulvestrant; median DOR 17.5mo.","Rolling NDA submission started under FDA RTOR; completion targeted Q4 2025.","PIK3CA mutant cohort fully enrolled; topline expected late Q1 2026 or Q2 2026.","Phase 1b data: median PFS 14.6mo in PIK3CA mutant patients overall, 19.7mo with intermittent dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139063,"accession_number":"0001641172-25-027025","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Celcuity upsizes senior secured facility to $500M, receives $30M immediate funding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total facility increased to $500M ($350M committed + $150M discretionary); $30M funded, total outstanding $130M.","Adds $100M upon FDA approval of gedatolisib in 2L wild-type advanced breast cancer; $120M upon commercial milestones.","Maturity extended to Nov 1, 2029; interest-only period extended by 14 months, with possible 7-month FDA-approval extension.","Issued warrants for 50,537 shares to lenders; cashless exercise through tenth anniversary of Term D funding.","Funds will support NDA rolling submission via FDA's RTOR program, commercial launch prep, and strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139062,"accession_number":"0001641172-25-024007","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity reports Phase 3 gedatolisib milestone; NDA filing on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 VIKTORIA-1: gedatolisib triplet reduced risk of progression/death by 76% (HR=0.24); median PFS 9.3 mo vs 2.0 mo.","NDA for gedatolisib based on PIK3CA wild-type cohort expected Q4 2025; PIK3CA mutant topline data also in Q4 2025.","Q2 2025 net loss $45.3M ($1.04/sh) vs $23.7M ($0.62/sh) in Q2 2024; operating expenses $44.0M.","Completed concurrent offerings of notes, stock, warrants with net proceeds $286.5M; proforma cash $455M funding through 2027.","New patent extends gedatolisib dosing regimen exclusivity into 2042; first patient dosed in Phase 3 VIKTORIA-2 first-line trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139061,"accession_number":"0001641172-25-021894","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Celcuity issues $201.25M of 2.750% convertible notes due 2031; net proceeds ~$194.5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $201.25M aggregate principal of 2.750% Convertible Senior Notes due 2031; initial conversion price ~$51.30/share.","Net proceeds of ~$194.5M after underwriting discounts and expenses; over-allotment option exercised in full.","Notes mature Aug 1, 2031; interest payable semiannually; redeemable at company's option after Aug 6, 2029 under conditions.","Company elected physical settlement for any conversions; notes are unsecured senior obligations.","Proceeds intended for working capital, R&D, clinical trials, and commercial launch expenditures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139060,"accession_number":"0001641172-25-021739","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celcuity prices $175M convertible notes and stock offering; net proceeds ~$248.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$175M of 2.750% convertible senior notes due 2031 priced; initial conversion price ~$51.30/share (35% premium to stock offering).","Common stock offering: 1,836,842 shares at $38.00/share + pre-funded warrants for 400,000 shares at $37.999/warrant.","Combined net proceeds ~$248.7M after underwriting discounts; use for working capital and general corporate purposes.","Company will not enter previously contemplated capped call transactions; investors may hedge via derivative transactions or selling shares.","Underwriters have 30-day options: up to $26.25M additional notes and up to 335,526 additional shares of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139059,"accession_number":"0001641172-25-021274","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celcuity launches $150M convertible notes + $75M common stock offerings; also to draw $30M loan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Concurrent underwritten offerings: $150M convertible notes due 2031 and $75M common stock; 30-day over-allotment options for additional $22.5M notes and $11.25M stock.","Proceeds to fund capped call transactions (reduce dilution on note conversion) and for working capital, clinical trials, R&D.","Intends to draw $30M Term D Loan in late August 2025 after achieving clinical milestone under existing loan agreement.","Amended loan with Innovatus/Oxford: $25k fee, extended conversion right on Term A loan to $10/share through May 9, 2026.","Preliminary cash at June 30, 2025: ~$168.4M (down from $283.1M a year ago)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139058,"accession_number":"0001641172-25-021095","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Celcuity Phase 3 VIKTORIA-1 PIK3CA wild-type: gedatolisib triplet cuts progression/death risk by 76% (HR 0.24)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gedatolisib triplet (plus palbociclib/fulvestrant) mPFS 9.3 mo vs 2.0 mo for fulvestrant, incremental gain 7.3 mo.","Gedatolisib doublet (plus fulvestrant) mPFS 7.4 mo vs 2.0 mo, reducing risk by 67% (HR 0.33; p<0.0001).","Treatment discontinuation due to AEs lower than prior Phase 1b; fewer hyperglycemia/stomatitis events.","Celcuity expects to submit NDA to FDA for gedatolisib in Q4 2025; mutation cohort topline by end of 2025.","Efficacy milestones: best HR and mPFS improvement ever reported in any Phase 3 for HR+/HER2- ABC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156581,"accession_number":"0001641172-25-017043","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Celcuity reports 66% six-month rPFS in mCRPC Phase 1, 43% ORR in HER2+ mBC Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 mCRPC (gedatolisib + darolutamide): 66% six-month rPFS; no treatment-related discontinuations or Grade 3 hyperglycemia; Grade 2-3 stomatitis in 10.5% of patients.","Phase 2 HER2+ mBC (gedatolisib + trastuzumab-pkrb): ORR 43%, median PFS 6.0 months, median OS 24.7 months; no discontinuations due to treatment-related AEs; 2.3% Grade 3 hyperglycemia.","Protocol amended to explore additional gedatolisib doses in mCRPC Phase 1/1b; up to six patients per arm in three arms, then Phase 1b with up to 40 patients to determine RP2D.","No prophylaxis for stomatitis used in the mBC trial; data cut-off Feb 10, 2025; results presented at ASCO June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156580,"accession_number":"0001641172-25-011273","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celcuity shareholders approve 3M-share increase under 2017 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved 3M share increase under 2017 Stock Incentive Plan (2.5M for ISOs).","All seven director nominees elected, including CEO Brian Sullivan.","Boulay PLLP ratified as independent auditor for FY2025.","Advisory say-on-pay approved with 25.4M For vs 0.8M Against.","Broker non-votes of 6.9M on director and say-on-pay matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156579,"accession_number":"0001641172-25-010308","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity reports Q1 net loss $37.0M; VIKTORIA-1 WT data expected Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.0M ($0.86/sh) vs $21.6M ($0.64/sh) in Q1 2024; non-GAAP adj. net loss $34.7M ($0.81/sh).","Cash, cash equivalents and investments of ~$206M at March 31, 2025, expected to fund operations through 2026.","VIKTORIA-1 PIK3CA wild-type cohort topline data now anticipated in Q3 2025; mutant cohort data in Q4 2025.","VIKTORIA-2 Phase 3 first patient dosing on track for Q2 2025; CELC-G-201 Phase 1b data expected late Q2 2025.","Clinical trial collaboration initiated with Dana Farber and Mass General for gedatolisib in endometrial cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174998,"accession_number":"0001641172-25-001698","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity posts Q4 net loss $36.7M, cash $235M, key trial data anticipated in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 net loss $36.7M ($0.85/share) vs $18.8M ($0.65/share) in Q4 2023; full year net loss $111.8M ($2.83/share).","Cash, cash equivalents and short-term investments of $235.1M at Dec 31, 2024, expected to fund operations through 2026.","PIK3CA wild-type cohort of VIKTORIA-1 Phase 3 topline data expected Q2 2025; mutant cohort data in Q4 2025.","VIKTORIA-2 Phase 3 first patient enrollment on track for Q2 2025; Phase 1b/2 mCRPC data expected late Q2 2025.","R&D expenses increased to $33.5M in Q4 from $18.1M, driven by ongoing and new clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191968,"accession_number":"0001493152-24-049089","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Celcuity establishes new $125M at-the-market equity offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM facility with Jefferies allows up to $125M additional common stock sales.","Prior ATM under 2022 agreement terminated; $27.8M in shares previously sold.","Shares offered under shelf registration declared effective Dec 2, 2024.","Prospectus supplement filed Dec 6, 2024; legal opinion by Faegre Drinker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191967,"accession_number":"0001493152-24-045804","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q3 net loss $29.8M ($0.70/sh); VIKTORIA-1 wild-type cohort 100% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PIK3CA wild-type cohort of VIKTORIA-1 100% enrolled; topline data expected late Q1 2025 or Q2 2025.","Celcuity reports Q3 2024 net loss $29.8M ($0.70/sh) vs $18.4M ($0.83/sh) in Q3 2023.","R&D expenses $27.6M, up from $17.5M; total operating expenses $30.1M.","Cash, cash equivalents and investments ~$264M at end of Q3 2024, expected to fund through 2026.","VIKTORIA-2 Phase 3 first patient enrollment expected Q2 2025; Phase 1b/2 mCRPC data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191966,"accession_number":"0001493152-24-040594","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"Celcuity shareholders approve increase in authorized shares from 65M to 95M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 31.38M for, 394K against, 1.9K abstain to amend charter.","Authorized common shares increased to 95M from 65M, effective Oct 7, 2024.","Adjournment proposal not required as sufficient votes were present.","Board previously approved the increase subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208421,"accession_number":"0001493152-24-032197","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q2 net loss widens to $23.7M; VIKTORIA-1 PIK3CA WT cohort enrollment delayed to Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.7M ($0.62/share) vs $14.6M ($0.66/share) YoY; non-GAAP adjusted loss per share $0.58.","R&D expenses rose to $22.5M, driven by VIKTORIA-1 Phase 3 and initiation of Phase 1b/2 mCRPC trial.","Raised $129M gross from equity and debt financings, extending cash runway through 2026.","VIKTORIA-1 PIK3CA WT cohort enrollment target shifted to Q4 2024; topline data expected late Q4 2024 to Q1 2025.","Plan to initiate Phase 3 VIKTORIA-2 trial in first-line HR+/HER2- advanced breast cancer; first patient expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226106,"accession_number":"0001493152-24-022227","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celcuity prices $60M common stock offering of 3.871M shares at $15.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,871,000 shares priced at $15.50 per share; gross proceeds $60.0M, net ~$56.2M.","Proceeds to fund working capital, R&D, and Phase 3 trial of gedatolisib for HR+/HER2- advanced breast cancer.","Investors include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital, Blue Owl Healthcare.","Offering closed May 31, 2024; existing cash plus proceeds expected to fund operations through at least H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226105,"accession_number":"0001493152-24-021864","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["1.01","8.01","2.03","3.02","9.01"],"status":"ready","headline":"Celcuity secures up to $180M debt financing, plans Phase 3 gedatolisib trial in HR+/HER2- breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New A&R Loan Agreement with Innovatus and Oxford provides up to $180M; $100M funded including $61.7M new borrowings.","Loan matures May 2029; interest-only for 36 months (extendable to 48 months) at Prime + 2.85% (floor 7.75%).","Phase 3 VIKTORIA-2 trial to enroll ~638 HR+/HER2- ABC patients; first patient expected Q2 2025.","Trial design allows investigator choice of ribociclib or palbociclib; FDA concurred in Type C meeting.","Warrants issued equal to 2.5% of each tranche; Innovatus can convert up to 20% of Term A at $10.00/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226104,"accession_number":"0001493152-24-019852","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q1 net loss $21.6M; Phase 3 VIKTORIA-1 on track for H2 2024 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.6M ($0.64/sh) vs $11.9M ($0.55/sh) in Q1 2023; cash $177.7M expected runway into H1 2026.","Phase 3 VIKTORIA-1 on track: topline PIK3CA wild-type data H2 2024; mutant sub-group H1 2025.","First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC; prelim data expected H1 2025.","Appointed Eldon Mayer as CCO in Feb 2024 to prepare for potential gedatolisib launch.","R&D expenses $20.7M (up $9.4M YoY) driven by VIKTORIA-1 and new trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226103,"accession_number":"0001493152-24-018943","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celcuity shareholders approve 1.5M share increase under 2017 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with votes for ranging from 18.5M to 19.0M (excluding broker non-votes).","Ratification of Boulay PLLP as auditor for FY2024 approved: 22,913,010 for, 1,149 against, 714 abstain.","Non-binding say-on-pay approved (18,099,226 for, 1,026,500 against); one-year frequency selected (18,867,130 for).","Plan amendments approved: 13,776,340 for the 1.5M share increase; 17,179,798 for the 250,000 per-person annual limit increase.","Effective May 9, 2024, total shares reserved under plan raised to 5,576,460, with annual evergreen increases through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245187,"accession_number":"0001493152-24-012030","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Celcuity extends Term C Loan draw deadline to June 1, 2024 via Second Amendment with Innovatus","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment extends Term C Draw Period from April 1, 2024 to June 1, 2024.","$10M Term C Loan available upon achievement of Term C Milestone and satisfaction of conditions.","First $15M loan drawn April 2021; $20M additional loan drawn December 2022.","No other changes to Loan Agreement; up to $75M total borrowing capacity unchanged.","Representations and warranties reaffirmed; no event of default (except existing defaults)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245186,"accession_number":"0001493152-24-011514","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q4 net loss $18.8M; FY net loss $63.8M; cash into H1 2026; VIKTORIA-1 topline data H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $18.8M ($0.65 loss per share) vs $11.6M ($0.69) in Q4 2022.","Full year 2023 net loss $63.8M ($2.69 per share) vs $40.4M ($2.64) in 2022.","Raised $65M from equity sale; cash expected to fund operations into first half of 2026.","Phase 3 VIKTORIA-1 trial on track to report topline data for PIK3CA wild type subgroup H2 2024.","First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC in February 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262640,"accession_number":"0001493152-23-043751","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celcuity raises $15M via equity sale of 1.03M shares at $14.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 1, 2023, sold 1,034,500 shares at $14.50 each, generating gross proceeds of $15M.","Approximately $29.8M of common stock remains available under the Open Market Sale Agreement with Jefferies.","As of Dec 5, 2023, cash, equivalents, and short-term investments were ~$185.3M.","Transaction executed under ATM facility established Feb 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262639,"accession_number":"0001493152-23-040317","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q3 net loss $18.4M; raises $50M; advances gedatolisib in prostate cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $18.4M ($0.83 loss per share) vs $10.9M ($0.75) YoY; non-GAAP adjusted loss $17.3M ($0.78).","Closed $50M private placement equity in October 2023; cash runway extended into mid-2026.","FDA cleared IND for gedatolisib + darolutamide in mCRPC; entered Bayer supply agreement for darolutamide.","VIKTORIA-1 Phase 3 (HR+/HER2- breast cancer) on track: PIK3CA wt data H2 2024, PIK3CA mut data H1 2025.","CELC-G-201 Phase 1b/2 (mCRPC) site activation Q1 2024; initial data expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262638,"accession_number":"0001493152-23-038005","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Celcuity raises $50M via private placement of pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from sale of pre-funded warrants to institutional investor.","Warrants purchase up to 5,747,787 shares at $8.70 each, exercise price $0.001/share.","Net proceeds to advance clinical development of gedatolisib and for general corporate purposes.","Warrants immediately exercisable; resale registration statement to be filed within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279828,"accession_number":"0001493152-23-030000","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celcuity adjusts executive compensation; CEO base salary down, CFO base up ~22% with stock options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO base salary decreased slightly; CSO base up <10%; CFO base up ~22% partially paid in stock options.","CSO and CFO each granted options for 21,250 shares as part of annual base salary, effective Aug 25, 2023.","Long-term incentive awards: 264,000 options to CEO (in two tranches), 125,000 to CSO, 60,000 to CFO.","Options vest over 48 months starting Aug 25, 2024; exercise price equals closing price on grant date.","All changes approved by Compensation Committee on Aug 23, 2023 to align with peer companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279827,"accession_number":"0001493152-23-029858","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Celcuity to start Phase 1b/2 trial of gedatolisib + darolutamide in mCRPC; Bayer supplies drug free","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for gedatolisib in combination with darolutamide; trial to begin Q1 2024.","Phase 1b/2 study CELC-G-201 will enroll up to 54 mCRPC patients who progressed after first-line AR inhibitor.","Bayer will provide Nubeqa (darolutamide) at no cost under clinical trial collaboration and supply agreement.","Virtual Science Day scheduled for September 21, 2023 (10:00 a.m. – 12:00 p.m. ET) with key opinion leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279826,"accession_number":"0001493152-23-027544","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q2 net loss $14.6M; Phase 1b gedatolisib data shows 48.6-month median PFS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M ($0.66/share) vs $10.0M ($0.67) Q2 2022; non-GAAP adjusted net loss $12.8M.","Cash, equivalents and short-term investments $146.2M at June 30; R&D $13.7M, up $5.4M on VIKTORIA-1.","Phase 3 VIKTORIA-1 on track; recruiting at ~200 sites in 20 countries; PIK3CA wild-type data H2 2024, mutant H1 2025.","Updated Phase 1b gedatolisib combo: median PFS 48.6 months, ORR 79% in 41 treatment-naïve HR+/HER2- advanced breast cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298280,"accession_number":"0001493152-23-017289","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q1 2023 net loss $11.9M; Phase 1b gedatolisib shows median PFS 48.6 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.9M ($0.55 loss per share) vs $7.9M ($0.53 loss per share) in Q1 2022.","R&D expenses $11.3M, up from $6.7M, driven by VIKTORIA-1 Phase 3 trial costs.","Cash and short-term investments $157.5M at March 31, 2023.","Phase 1b gedatolisib data: median PFS 48.6 months in treatment-naïve HR+/HER2- advanced breast cancer.","VIKTORIA-1 Phase 3 enrollment on track for primary analysis of PIK3CA WT subgroup in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298279,"accession_number":"0001493152-23-016627","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celcuity shareholders approve 1.5M share increase under 2017 stock incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved amendment to increase shares reserved for issuance under the 2017 Plan by 1,500,000 shares (to 3,821,400 total).","All seven director nominees elected (e.g., Richard E. Buller, David F. Dalvey, Leo T. Furcht, etc.).","Ratified appointment of Boulay PLLP as independent registered public accounting firm for fiscal year ending Dec 31, 2023.","Non-binding advisory vote approved named executive officer compensation (9,248,453 for, 3,577,453 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318531,"accession_number":"0001493152-23-008693","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q4/FY2022 net loss $11.6M/$40.4M; cash runway extended through 2025 after $100M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $11.6M ($0.69/sh); full year net loss $40.4M ($2.64/sh).","Dosed first patient in Phase 3 VIKTORIA-1 trial, triggering $100M PIPE closing and $20M term loan drawdown.","Cash runway expected through 2025; combined with debt facility and existing cash.","Updated Phase 1b data at SABCS: median PFS 42.3 months in treatment-naive advanced breast cancer.","Enrollment ongoing in FACT-1/2 for CELsignia; interim results expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318530,"accession_number":"0001493152-23-007785","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Celcuity extends office lease through April 2026; monthly rent $18K–$18.5K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended term to April 30, 2026 per Fourth Amendment to Lease with West Glen Development.","Base rent: $18,012.27/month (May 2024–Apr 2025); $18,542.44/month (May 2025–Apr 2026).","No broker commissions due; premises accepted as-is with all other lease terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318529,"accession_number":"0001493152-23-007302","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Celcuity discloses SVB exposure less than 0.4% of $168M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Uninsured balance at Silicon Valley Bank is less than 0.4% of total cash, cash equivalents, and short-term investments.","Total cash, equivalents, and short-term investments were approximately $168 million at December 31, 2022.","Separate custodian holds Celcuity’s investments; they are not exposed to SVB liquidity concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336773,"accession_number":"0001493152-22-036496","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Celcuity closes $20M term loan from Innovatus under existing credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $20.0M Term B Loan on Dec 22, 2022; part of previously disclosed $75M facility.","Interest rate is greater of prime rate or 3.25% plus 5.70%; maturity April 8, 2027.","Interest-only payments until May 1, 2025 (or May 1, 2026 if conditions met); 4.95% PIK elected.","Innovatus can convert up to $6.6M of principal into common stock at $10.00 per share.","Loan is secured by all assets; proceeds for working capital and general business needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336772,"accession_number":"0001493152-22-031332","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celcuity Q3 net loss $10.9M ($0.75/sh); Phase 3 VIKTORIA-1 site activation underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.9M ($0.75/sh) vs $6.0M ($0.41/sh) in Q3 2021; adjusted net loss $9.5M ($0.63/sh).","R&D expenses $9.6M, up $4.7M YoY, mainly from VIKTORIA-1 trial initiation and existing trials.","Completed selection of 200 clinical sites for Phase 3 VIKTORIA-1; first site activated; first dosing expected by end of 2022.","FDA granted Breakthrough Therapy designation for gedatolisib in July; $100M private placement to close after first patient dose.","Appointed Polly Murphy to Board; Phase 1b update accepted for December 2022 San Antonio Breast Cancer Symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336771,"accession_number":"0001493152-22-031158","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K/A","filed_at":"2022-11-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celcuity appoints Polly A. Murphy to Audit and Compensation Committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Appointment effective November 9, 2022.","Dr. Murphy joins the Audit Committee and the Compensation Committee.","Board determined she meets Nasdaq and Exchange Act requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354154,"accession_number":"0001493152-22-025891","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["1.01","3.03","5.02","9.01"],"status":"ready","headline":"Celcuity appoints Dr. Polly Murphy to Board; reduces warrant shares to 70K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warrant amended: shares reduced from 138,000 to 70,000; exercise period extended to Sept 19, 2025.","Board expanded to 7 directors; Dr. Polly Murphy elected as independent director, effective immediately.","Dr. Murphy brings 20+ years of pharma biz dev experience including 12 years at Pfizer; currently CBO of UroGen Pharma.","Dr. Murphy granted options: 16,300 shares vesting by 2023 annual meeting or April 30, 2023; plus 10,000 shares vesting over 4 years.","Company expects to dose first patient in Phase 3 gedatolisib study for HR+/HER2- breast cancer in next few months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354153,"accession_number":"0001493152-22-024841","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Celcuity shareholders approve increase in authorized shares from 30M to 65M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["At Sept 1, 2022 Special Meeting, Proposal 1 (share increase) passed with 11,636,957 For, 173,221 Against, 2,305 Abstain.","Authorized common stock raised from 30,000,000 to 65,000,000 shares.","Proposal 2 (adjournment to solicit more votes) was not needed and not voted upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354152,"accession_number":"0001493152-22-022062","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Celcuity expands debt to $75M, Q2 net loss $10M, gedatolisib gets Breakthrough Therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Debt facility amended to up to $75M ($50M increase); $15M drawn, $20M due on private placement close; other tranches tied to clinical milestones.","Q2 2022 net loss $10.0M ($0.67 loss per share) vs $14.0M ($1.11) in Q2 2021; non-GAAP adjusted loss $8.3M ($0.55).","FDA granted Breakthrough Therapy designation in July for gedatolisib in HR+/HER2- metastatic breast cancer.","Private placement of $100M equity signed May 2022; closing expected after first patient dosed in VIKTORIA-1.","VIKTORIA-1 Phase 3 trial on track to dose first patient shortly; FACT-1/2 interim data expected mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354151,"accession_number":"0001493152-22-020778","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Celcuity extends office lease by one year through April 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Third Amendment to Lease extends term to April 30, 2024.","Base rent from May 2023 through April 2024: $17,359.75 per month.","Landlord is West Glen Development I, LLC; tenant Celcuity Inc.","Premises located at 16305 36th Avenue North, Plymouth, Minnesota.","Lease accepted 'as is' with no warranty; no brokerage commissions due."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372038,"accession_number":"0001493152-22-014511","cik":1603454,"company_name":"Celcuity Inc.","ticker":"CELC","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celcuity grants stock options to execs in lieu of salary, reprices outstanding options to $5.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Brian Sullivan granted options for 250,000 shares in lieu of 14-month base salary starting June 1, 2022.","CSO Lance Lang and CFO Vicky Hahne granted options (38,412 and 31,930) in lieu of salary increases.","Options have exercise price of $5.50 per share, vesting monthly over 14 months.","Additionally, 781,324 previously issued options (weighted avg exercise price $15.82) repriced to $5.50.","Repriced options held by directors and named execs (347,433 options) originally had weighted avg price $19.87."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6428372242.221991,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-19T23:59:59+00:00|372038"}